Klein S M, Elmer G W, McFarland L V, Surawicz C M, Levy R H
Department of Pharmaceutics, University of Washington, Seattle 98195.
Pharm Res. 1993 Nov;10(11):1615-9. doi: 10.1023/a:1018924820333.
Saccharomyces boulardii (Sb) is a nonpathogenic yeast used to treat intestinal illnesses such as pseudomembranous colitis and antibiotic associated diarrhea. The behavior of this biotherapeutic agent in humans was determined (1) in investigating the effect of dose on the steady-state level and recovery and (2) in quantitating the effect of ampicillin on the recovery and elimination profile. As the Sb dose increased, the mean steady-state concentration of Sb increased significantly. The percentage recovery was dose independent. When a single Sb dose was administered 24 hr after beginning a course of ampicillin, there was a significant increase (P < 0.01) in both the area under the concentration versus time curve and the maximum fecal concentration compared to values obtained without ampicillin. Ampicillin increased steady-state recovery of the drug about twofold (P < 0.05) and steady-state levels about 2.4 times (P < 0.01). These studies have shown that there is a relationship between the dose and the amount of Sb recovered and that perturbation of the GI flora by ampicillin increases steady-state levels of Sb.
布拉氏酵母菌（Sb）是一种用于治疗肠道疾病如伪膜性结肠炎和抗生素相关性腹泻的非致病性酵母。这种生物治疗剂在人体中的行为通过以下方式确定：（1）研究剂量对稳态水平和恢复的影响；（2）定量氨苄西林对恢复和消除曲线的影响。随着Sb剂量增加，Sb的平均稳态浓度显著增加。恢复百分比与剂量无关。在开始氨苄西林疗程24小时后给予单次Sb剂量时，与未使用氨苄西林时获得的值相比，浓度-时间曲线下面积和最大粪便浓度均显著增加（P < 0.01）。氨苄西林使药物的稳态恢复增加约两倍（P < 0.05），稳态水平增加约2.4倍（P < 0.01）。这些研究表明，剂量与Sb恢复量之间存在关系，并且氨苄西林对胃肠道菌群的干扰会增加Sb的稳态水平。
